Search results for " Markov chain"

showing 10 items of 52 documents

Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

2018

Abstract Background & Aims Advances in direct‐acting antiviral treatment of HCV have reinvigorated public health initiatives aimed at identifying affected individuals. We evaluated the possible impact of only diagnosed and linked‐to‐care individuals on overall HCV burden estimates and identified a possible strategy to achieve the WHO targets by 2030. Methods Using a modelling approach grounded in Italian real‐life data of diagnosed and treated patients, different linkage‐to‐care scenarios were built to evaluate potential strategies in achieving the HCV elimination goals. Results Under the 40% linked‐to‐care scenario, viraemic burden would decline (60%); however, eligible patients to treat w…

HCV; WHO; chronic infection; linkage to careLiver Cirrhosismedicine.medical_specialtyCarcinoma HepatocellularSustained Virologic ResponseViral HepatitisSettore MED/12 - GASTROENTEROLOGIAWorld Health OrganizationAntiviral AgentsNO03 medical and health sciencesLiver diseaseWHO0302 clinical medicinePharmacotherapyCost of IllnessCause of DeathHealth caremedicineHumans030212 general & internal medicineViremiachronic infection HCV linkage to care WHODisease EradicationMortalityIntensive care medicineCause of deathlinkage to carechronic infection; HCV; linkage to care; WHODisease EradicationHepatologybusiness.industryPublic healthCarcinomaLiver NeoplasmsHepatocellularHepatitis Cmedicine.diseasechronic infectionHepatitis CMarkov Chainschronic infection; HCV; linkage to care; WHO; Antiviral Agents; Carcinoma Hepatocellular; Cost of Illness; Disease Eradication; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Markov Chains; Mortality; Sustained Virologic Response; Viremia; World Health Organization; Cause of DeathItalychronic infection;HCV;linkage to care;WHOHCVchronic infection; HCV; linkage to care; WHO; Hepatology030211 gastroenterology & hepatologybusinessViral hepatitis
researchProduct

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

2019

OBJECTIVE:\ud We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy.\ud \ud METHODS:\ud A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulativ…

Liver CirrhosisPediatricsTime FactorsSettore MED/09 - Medicina InternaNational Health ProgramsERADICATIONOUTBREAKantiviral treatment anti HCV economic consequencesHepacivirusLIVER FIBROSISSeverity of Illness IndexHealth Services AccessibilityCOST-EFFECTIVENESSIndirect costs0302 clinical medicineEpidemiologyvirus infection030212 general & internal medicinehealth care economics and organizationscost effectiveness030503 health policy & servicesHealth PolicyHealth services researchhealthHepatitis CHepatitis CMarkov Chainschronic hepatitis C virus infection fibrosis progression cost effectiveness liver fibrosisItalyPharmacology; Health Policy; Public Health Environmental and Occupational HealthCohortSettore SECS-P/03 - Scienza delle FinanzeDisease ProgressionPublic Health0305 other medical scienceViral hepatitisAnti-HCV antiviral treatmentCHRONIC HEPATITIS-Cmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAVIRUS-INFECTIONAntiviral AgentsNO03 medical and health sciencesCost SavingsAntiviral Agents; Cost Savings; Disease Progression; Genotype; Health Policy; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Markov Chains; National Health Programs; Severity of Illness Index; Time FactorsmedicineMANAGEMENTHumanschronic hepatitis CINDUCED DISEASESMETAANALYSISPharmacologyHealth economicsbusiness.industryPublic healthEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthmedicine.diseaseFIBROSIS PROGRESSIONbusiness
researchProduct

Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?

2016

In Italy, the Italian Pharmaceutical Agency (AIFA) criteria used F3–F4 fibrosis stages as the threshold to prioritise the treatment with interferon (IFN)-free regimens, while in genotype 1 chronic hepatitis C (G1 CHC) patients with fibrosis of liver stage 2, an approach with pegylated interferon (PEG-IFN)-based triple therapy with simeprevir was suggested. The key clinical question is whether, in an era of financial constraints, the application of a universal IFN-free strategy in naive G1 CHC patients is feasible within a short time horizon. The aim of this study is to perform an economic analysis to estimate the cost-utility of the early innovative therapy in Italy for managing hepatitis C…

Liver CirrhosisSimeprevirmedicine.medical_specialtyCost-Benefit AnalysisPopulationAntiviral Agents03 medical and health sciencesIndirect costs0302 clinical medicineAntiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis C Chronic; Humans; Interferons; Italy; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Treatment Outcome; Pharmacology (medical)SimeprevirRibavirinmedicineHumansPharmacology (medical)030212 general & internal medicineChronicIntensive care medicineeducationReimbursementeducation.field_of_studyCost–benefit analysisbusiness.industryHealth services researchGeneral MedicineHepatitis CHepatitis C Chronicmedicine.diseaseHepatitis CMarkov ChainsQuality-adjusted life yearTreatment OutcomeItalyDisease Progression030211 gastroenterology & hepatologyInterferonsQuality-Adjusted Life YearsbusinessMonte Carlo MethodClinical Drug Investigation
researchProduct

Variable length Markov chains and dynamical sources

2010

Infinite random sequences of letters can be viewed as stochastic chains or as strings produced by a source, in the sense of information theory. The relationship between Variable Length Markov Chains (VLMC) and probabilistic dynamical sources is studied. We establish a probabilistic frame for context trees and VLMC and we prove that any VLMC is a dynamical source for which we explicitly build the mapping. On two examples, the ``comb'' and the ``bamboo blossom'', we find a necessary and sufficient condition for the existence and the unicity of a stationary probability measure for the VLMC. These two examples are detailed in order to provide the associated Dirichlet series as well as the gener…

MSC 60J05 MSC 37E05[MATH.MATH-PR] Mathematics [math]/Probability [math.PR]Probability (math.PR)[MATH.MATH-DS]Mathematics [math]/Dynamical Systems [math.DS][ MATH.MATH-DS ] Mathematics [math]/Dynamical Systems [math.DS]Probabilistic dynamical sources[MATH.MATH-DS] Mathematics [math]/Dynamical Systems [math.DS]Dynamical Systems (math.DS)Variable length Markov chainsOccurrences of words[MATH.MATH-PR]Mathematics [math]/Probability [math.PR]60J05 37E05FOS: MathematicsMathematics - Dynamical SystemsDynamical systems of the intervalDirichlet series[ MATH.MATH-PR ] Mathematics [math]/Probability [math.PR]Mathematics - Probability
researchProduct

Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma

2013

The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular carcinoma (HCC) patients incorporating current prices and the results of the recent published field practice SOraFenib Italian Assessment (SOFIA) study. We created a Markov Decision Model to evaluate, in a hypothetical cohort of Caucasian male patients, aged 67 years with Barcelona Clinic Liver Cancer (BCLC) C HCC, or BCLC B HCC who were unfit or failed to respond to locoregional therapies, well compensated cirrhosis, and with performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG), the cost-effectiveness of the following strategies: (1) full or dose-adjusted sorafenib for …

MaleNiacinamideOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularCost effectivenessCost-Benefit AnalysisSettore MED/12 - GASTROENTEROLOGIAAged; Antineoplastic Agents; Carcinoma Hepatocellular; Cost-Benefit Analysis; Drug Costs; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality-Adjusted Life YearsAntineoplastic AgentsKaplan-Meier EstimateDrug CostsInternal medicinemedicineHumansProspective StudiesProspective cohort studyneoplasmsSurvival rateAgedHepatologyPerformance statusbusiness.industryPhenylurea CompoundsLiver NeoplasmsCarcinomaHepatocellular carcinoma sorafenib ICER cost-effectivenessHepatocellularSorafenibmedicine.diseaseMarkov Chainsdigestive system diseasesSurgeryQuality-adjusted life yearHepatocellular carcinomaMultivariate AnalysisQuality-Adjusted Life YearsbusinessLiver cancermedicine.drugHepatology
researchProduct

Increased Activity of Coagulation Factor XII (Hageman Factor) Causes Hereditary Angioedema Type III

2006

International audience; Hereditary angioedema (HAE) is characterized clinically by recurrent acute skin swelling, abdominal pain, and potentially life-threatening laryngeal edema. Three forms of HAE have been described. The classic forms, HAE types I and II, occur as a consequence of mutations in the C1-inhibitor gene. In contrast to HAE types I and II, HAE type III has been observed exclusively in women, where it appears to be correlated with conditions of high estrogen levels--for example, pregnancy or the use of oral contraceptives. A recent report proposed two missense mutations (c.1032C-->A and c.1032C-->G) in F12, the gene encoding human coagulation factor XII (FXII, or Hageman factor…

MaleTime FactorsKinins030204 cardiovascular system & hematologyMESH: Founder Effect[SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunityLinkage Disequilibrium0302 clinical medicineMissense mutationHereditary Angioedema Type IIIGenetics(clinical)MESH: Models GeneticGenetics (clinical)MESH: Heterozygote0303 health sciencesFactor XII[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyFounder EffectMarkov ChainsPedigree3. Good healthMESH: Linkage DisequilibriumFactor XIIHereditary angioedemaFemalemedicine.symptomMESH: Factor XIIHeterozygotemedicine.medical_specialtyMESH: MutationMESH: PedigreeMESH: Bayes TheoremCoagulation Factor XIIBiology03 medical and health sciencesMESH: Markov ChainsReportInternal medicinemedicineGeneticsHumansMESH: AngioedemaAngioedema030304 developmental biologyMESH: HumansModels GeneticAngioedemaHaplotypeMESH: Time FactorsBayes TheoremHeterozygote advantageMESH: Haplotypesmedicine.diseaseMESH: KininsMESH: MaleEndocrinologyHaplotypesMutationImmunologyMESH: Microsatellite RepeatsMESH: FemaleMicrosatellite RepeatsThe American Journal of Human Genetics
researchProduct

Robust Assembly Assistance Using Informed Tree Search with Markov Chains

2022

Manual work accounts for one of the largest workgroups in the European manufacturing sector, and improving the training capacity, quality, and speed brings significant competitive benefits to companies. In this context, this paper presents an informed tree search on top of a Markov chain that suggests possible next assembly steps as a key component of an innovative assembly training station for manual operations. The goal of the next step suggestions is to provide support to inexperienced workers or to assist experienced workers by providing choices for the next assembly step in an automated manner without the involvement of a human trainer on site. Data stemming from 179 experiment partici…

Markov chainsChemical technologytraining stationsTP1-1185predictionIndustry 4.0artificial intelligenceBiochemistryArticleAtomic and Molecular Physics and OpticsAnalytical ChemistryA* algorithmassembly assistance systems; training stations; smart manufacturing; Industry 4.0; digital transformation; informed tree search; A* algorithm; Markov chains; prediction; artificial intelligenceinformed tree searchHumansdigital transformationassembly assistance systemssmart manufacturingElectrical and Electronic EngineeringInstrumentationAlgorithmsSensors; Volume 22; Issue 2; Pages: 495
researchProduct

Greedy versus Dynamic Channel Aggregation Strategy in CRNs: Markov Models and Performance Evaluation

2011

Part 1: - PE-CRN 2011 Workshop; International audience; In cognitive radio networks, channel aggregation techniques which aggregate several channels together as one channel have been proposed in many MAC protocols. In this paper, we consider elastic data traffic and spectrum adaptation for channel aggregation, and propose two new strategies named as Greedy and Dynamic respectively. The performance of channel aggregation represented by these strategies is evaluated using continuous time Markov chain models. Moreover, simulation results based on various traffic distributions are utilized in order to evaluate the validity and preciseness of the mathematical models.

Mathematical optimizationMathematical modelComputer science020209 energycontinuous time Markov chain modelsAggregate (data warehouse)Cognitive radio networks020206 networking & telecommunications02 engineering and technologyMarkov modelchannel aggregation strategyperformance evaluationContinuous-time Markov chain[INFO.INFO-NI]Computer Science [cs]/Networking and Internet Architecture [cs.NI]Cognitive radio0202 electrical engineering electronic engineering information engineeringDynamic channel[INFO]Computer Science [cs]SimulationComputer Science::Information TheoryCommunication channel
researchProduct

$\texttt{HEPfit}$: a Code for the Combination of Indirect and Direct Constraints on High Energy Physics Models

2020

The European physical journal / C Particles and fields C80(5), 456 (2020). doi:10.1140/epjc/s10052-020-7904-z

Physics and Astronomy (miscellaneous)Physics beyond the Standard ModelMonte Carlo methoddoublet: 2 [Higgs particle]Parameter space01 natural sciencesMonte Carlo: Markov chainHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)effective field theoryHigh Energy Physics - Phenomenology (hep-ph)[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Statistical physicsStandard model (cryptography)Physicsnew physicsHiggs particle: doublet: 2statistical analysis: BayesianObservablehep-phHigh Energy Physics - PhenomenologysymbolsParticle Physics - Experimentcorrection: obliqueBayesian probabilityFOS: Physical scienceslcsh:AstrophysicsMarkov chain [Monte Carlo]Bayesian [statistical analysis]530programmingSet (abstract data type)oblique [correction]symbols.namesake0103 physical scienceslcsh:QB460-466operator: dimension: 6ddc:530lcsh:Nuclear and particle physics. Atomic energy. Radioactivity010306 general physicsnumerical calculationsEngineering (miscellaneous)Particle Physics - Phenomenology010308 nuclear & particles physicshep-exMarkov chain Monte Carlomanual[PHYS.HPHE]Physics [physics]/High Energy Physics - Phenomenology [hep-ph]lcsh:QC770-798dimension: 6 [operator]
researchProduct

System Times and Channel Availability for Secondary Transmissions in CRNs: A Dependability Theory based Analysis

2017

[EN] Reliability is of fundamental importance for the performance of secondary networks in cognitive radio networks (CRNs). To date, most studies have focused on predicting reliability parameters based on prior statistics of traffic patterns from user behavior. In this paper, we define a few reliability metrics for channel access in multichannel CRNs that are analogous to the concepts of reliability and availability in classical dependability theory. Continuous-time Markov chains are employed to model channel available and unavailable time intervals based on channel occupancy status. The impact on user access opportunities based on channel availability is investigated by analyzing the stead…

Reliability theoryComputer Networks and CommunicationsComputer scienceAerospace Engineering02 engineering and technologyCommunications system0203 mechanical engineering0202 electrical engineering electronic engineering information engineeringDependabilityCognitive radio networks (CRNs)Resource managementElectrical and Electronic EngineeringSpectrum accessMarkov chainCumulative distribution functionGuaranteed availability020206 networking & telecommunications020302 automobile design & engineeringINGENIERIA TELEMATICAUniformization (probability theory)System timesReliability engineeringCognitive radioChannel availabilityAutomotive EngineeringContinuous-time Markov chains (CTMCs)UnavailabilityCommunication channel
researchProduct